Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)

References

• Fietz M, AlSayed M, Burke D, et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): expert recommendations for early detection and laboratory diagnosis. Mol Genet Metab. 2016;119(1–2):160–167. DOI:10.1016/j.ymgme.2016.07.011
   PubMed Web of Science ®Google Scholar
• Geraets RD, Koh S, Hastings ML, et al. Moving towards effective therapeutic strategies for neuronal ceroid lipofuscinosis. Orphanet J Rare Dis. 2016;11(1):40. DOI:10.1186/s13023-016-0414-2
   PubMedGoogle Scholar
• Johnson AM, Mandelstam S, Andrews I, et al. Neuronal ceroid lipofuscinosis type 2: an Australian case series. J Paediatr Child Health. 2020;56(8):1210–1218. DOI:10.1111/jpc.14890
   PubMed Web of Science ®Google Scholar
• Aylward SC, Pindrik J, Abreu NJ, et al. Cerliponase alfa for CLN2 disease, a promising therapy. Expert Opin Orphan Drugs. 2020;8:445–454. .
   Web of Science ®Google Scholar
• Lewis G, Morrill AM, Conway-Allen SL, et al. Review of cerliponase alfa: recombinant human enzyme replacement therapy for late-infantile neuronal ceroid lipofuscinosis type 2. J Child Neurol. 2020;35(5):348–353. DOI:10.1177/0883073819895694
   PubMed Web of Science ®Google Scholar
• de Los Reyes E, Lehwald L, Augustine EF, et al. Intracerebroventricular cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease: clinical practice considerations from US Clinics. Pediatr Neurol. 2020;110:64–70.
   PubMed Web of Science ®Google Scholar
• Mole SE, Anderson G, Band HA, et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 2019;18(1):107–116. DOI:10.1016/S1474-4422(18)30368-5
   PubMed Web of Science ®Google Scholar
• Williams RE, Adams HR, Blohm M, et al. Management strategies for CLN2 disease. Pediatr Neurol. 2017;69:102–112.
   PubMed Web of Science ®Google Scholar
• Clinical review report: cerliponase alfa (brineura): (BioMarin Pharmaceutical (Canada) Inc.): indication: for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun. Introduction. [cited 1 Oct 2022]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544816/.
   Google Scholar
• Schulz A, Ajayi T, Specchio N, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378(20):1898–1907. DOI:10.1056/NEJMoa1712649. .
   PubMed Web of Science ®Google Scholar
• de Souza Mv, Krug BC, Picon PD, et al. [High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders]. Cien Saude Colet. 2010;15(3):3443–3454. DOI:10.1590/s1413-81232010000900019
   PubMedGoogle Scholar
• Kanters TA, van der Ploeg AT, Kruijshaar ME, et al. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Orphanet J Rare Dis. 2017;12(1):179. DOI:10.1186/s13023-017-0731-0
   PubMedGoogle Scholar
• Gutić M, Milosavljević MN, Janković SM. Cost-effectiveness of miglustat versus symptomatic therapy of Niemann–Pick disease type C. Int J Clin Pharm. 2022;44(6):1442–1453. . DOI:10.1007/s11096-022-01491-8
   PubMed Web of Science ®Google Scholar
• WDI – Classifying countries by income. [Internet]. [cited 1 Oct 2022]. Available from: https://datatopics.worldbank.org/world-development-indicators/stories/the-classification-of-countries-by-income.html.
   Google Scholar
• Parliament of Republic of Serbia. Health Insurance Law. Off Gaz RS. 2019. [Internet]. [cited 1 Oct 2022]. Available from: https://www.paragraf.rs/propisi/zakon_o_zdravstvenom_osiguranju.html.
   Google Scholar
• National Centre for Pharmacoeconomics. Cost-effectiveness of cerliponase alfa (Brineura®) for the treatment of patients with CLN2 disease. [Internet]. [cited 1 Oct 2022]. Available from:https://www.ncpe.ie/wp-content/uploads/2017/11/Summary-CLN-alfa-26.03.2019.pdf.
   Google Scholar
• Nickel M, Simonati A, Jacoby D, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018;2(8):582–590. DOI:10.1016/S2352-4642(18)30179-2. .
   PubMedGoogle Scholar
• Steinfeld R, Heim P, von Gregory H, et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet. 2002;112(4):347–354. DOI:10.1002/ajmg.10660
   PubMed Web of Science ®Google Scholar
• Pérez-Poyato MS, Marfa MP, Abizanda IF, et al. Late infantile neuronal ceroid lipofuscinosis: mutations in the CLN2 gene and clinical course in Spanish patients. J Child Neurol. 2013;28(4):470–478. DOI:10.1177/0883073812448459
   PubMed Web of Science ®Google Scholar
• Gissen P, Specchio N, Olaye A, et al. Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2). Orphanet J Rare Dis. 2021;16(1):217. DOI:10.1186/s13023-021-01829-x
   PubMed Web of Science ®Google Scholar
• Vergeer M, de Ranitz-Greven WL, Neary MP, et al. Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex. Epilepsia Open. 2019;4:581–592.
   PubMedGoogle Scholar
• Chittrakul J, Siviroj P, Sungkarat S, et al. Multi-system physical exercise intervention for fall prevention and quality of life in pre-frail older adults: a randomized controlled trial. Int J Environ Res Public Health. 2020;17(9):3102. DOI:10.3390/ijerph17093102
   PubMed Web of Science ®Google Scholar
• Varni JW, Nutakki K, Swigonski NL. Speech difficulties and patient health communication mediating effects on worry and health-related quality of life in children, adolescents, and young adults with Neurofibromatosis Type 1. Am J Med Genet A. 2019;179:1476–1482.
   PubMed Web of Science ®Google Scholar
• Marciano RC, Cardoso MGF, Vasconcelos MA, et al. Behavioral disorders and impairment of quality of life in children and adolescents with lower urinary tract dysfunction. J Pediatr Urol. 2018;14(6):.e568.1–568.7. DOI:10.1016/j.jpurol.2018.07.017
   Web of Science ®Google Scholar
• Rowen D, Mulhern B, Banerjee S, et al. Comparison of general population, patient, and carer utility values for dementia health states. Med Decis Mak. 2015;35:68–80.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Gavriel S, et al. Health utility values associated with diabetic retinopathy. Diabet Med. 2008;25(5):618–624. DOI:10.1111/j.1464-5491.2008.02430.x
   PubMed Web of Science ®Google Scholar
• Mikulić I, Likić R, Janković SM. Cost-effectiveness of zonisamide versus levetiracetam in newly diagnosed focal onset epilepsy in serbia. Value Health Reg Issues. 2022;27:49–57.
   PubMedGoogle Scholar
• Davis JC, Dian L, Khan KM, et al. Cognitive status is a determinant of health resource utilization among individuals with a history of falls: a 12-month prospective cohort study. Osteoporos Int. 2016;27(3):943–951. DOI:10.1007/s00198-015-3350-4
   PubMed Web of Science ®Google Scholar
• Liu Z, Huang J, Xu Y, et al. Cost-effectiveness of speech and language therapy plus scalp acupuncture versus speech and language therapy alone for community-based patients with Broca’s aphasia after stroke: a post hoc analysis of data from a randomised controlled trial. BMJ Open. 2021;11(9):e046609. DOI:10.1136/bmjopen-2020-046609
   PubMedGoogle Scholar
• Wimo A, Jönsson L, Gustavsson A, et al. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry. 2011;26(8):825–832. DOI:10.1002/gps.2610
   PubMed Web of Science ®Google Scholar
• Wu EQ, Hodgkins P, Ben-Hamadi R, et al. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. CNS Drugs. 2012;26:581–600.
   PubMed Web of Science ®Google Scholar
• Marques AP, Ramke J, Cairns J, et al. The economics of vision impairment and its leading causes: a systematic review. EclinicalMedicine. 2022;46:101354.
   PubMedGoogle Scholar
• Shaw G. Practice matters: sky-high costs of breakthrough drugs challenge neurology: how some practices are addressing It. Neurology Today. 2017;17:1.
   Google Scholar
• Statistical Office of the Republic of Serbia 2022. [Internet]. [cited 1 Oct 2022]. Available from: https://data.stat.gov.rs/Home/Result/09020101?languageCode=sr-Cyrl.
   Google Scholar
• National Bank of Serbia. Interest rates. [Internet]. 2021. [Internet]. [cited 1 Oct 2022]. Available from: https://www.nbs.rs/sr/ciljevi-i-funkcije/monetarna-politika/kamatne-stope/.
   Google Scholar
• Republic Health Insurance Fund of Serbia. Rulebook on the prices of health services at the secondary and tertiary levels of health care. Off Gaz RS. 55/2019, 53/2021
   Google Scholar
• Republic Health Insurance Fund of Serbia. Rulebook on the list of medicines prescribed and issued at the expense of compulsory health insurance funds. Off Gaz RS. 2019. 43/19, 55/19, 56/19-correction, 73/19, 87/19, 18/20, 43/20, 108/20, 49/21, 51/21-correction and 60/21
   Google Scholar
• The Government of the Republic of Serbia. Decision on the highest prices of prescription medicines for human use. Off Gaz RS. 2021. 48/2021
   Google Scholar
• Karnon J, Haji Ali Afzali H. When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES. Pharmacoeconomics. 2014;32:547–558.
   PubMed Web of Science ®Google Scholar
• Jankovic SM Discrete-event simulation model for comparison of cost-effectiveness of cerliponase alfa vs. symptomatic therapy in patients with late neuronal lipofuscinosis type 2. 2022. [Internet]. [cited 1 Oct 2022]. Available from: https://docs.google.com/spreadsheets/d/1VP2S9IagPnvvjrUxkVhn_YruZLa2O6Vt/edit#gid=1401080500.
   Google Scholar
• Food, Administration D. FDA news release. FDA approves first treatment for a form of batten disease. [Internet]. [cited 1 Oct 2022]. ymptome from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-form-batten-disease.
   Google Scholar
• European Medical Agency. EPAR summary for the public. Brineura (cerliponase alfa). [Internet]. [cited 1 Oct 2022]. Available from: https://www.ema.europa.eu/en/documents/overview/brineura-epar-summary-public_en.pdf.
   Google Scholar
• Food and Drug Administration. Brineura- highlights of prescribing information. [Internet]. [cited 1 Oct 2022]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761052lbl.pdf.
   Google Scholar
• Pharmacoeconomic review report: cerliponase Alfa (Brineura): (BioMarin Pharmaceutical (Canada) Inc.): indication: for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun. Appendix 1, Cost Comparison. [cited 1 Oct 2022]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544832/.
   Google Scholar
• CADTH Canadian Drug Expert Committee Recommendation: Cerliponase Alfa (Brineura — BioMarin Pharmaceutical [Canada] Inc.): indication: for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May. [cited 1 Oct 2022]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK543392/.
   Google Scholar
• Mortensen A, Raebel EM, Wiseman S. Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment. Orphanet J Rare Dis. 2022;17(1):19.
   PubMed Web of Science ®Google Scholar
• National Centre for Pharmacoeconomics. NCPE Ireland. Cost-effectiveness of cerliponase alfa (Brineura®) for the treatment of patients with CLN2 disease. [Internet]. [cited 1 Oct 2022]. Available at: https://www.ncpe.ie/wp-content/uploads/2017/11//Summary-CLN-alfa-26.03.2019.pdf
   Google Scholar
• Alkhatib NS, Ramos K, Erstad B, et al. Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing. J Med Econ. 2020;23(11):1223–1229. DOI:10.1080/13696998.2020.1815026
   PubMed Web of Science ®Google Scholar
• Caso-González A, Núñez-Rodríguez J, Nebot-Villacampa MJ, et al. Experiencia clínica con medicamentos huérfanos para enfermedades raras metabólicas [Clinical experience with orphan drugs for rare metabolic diseases]. AnPediatr [Engl ED]. 2020:S1695-4033(20)30437-9.
   Google Scholar
• Holmerová I, Hort J, Rusina R, et al. Costs of dementia in the Czech Republic. Eur J Health Econ. 2017;18(8):979–986. DOI:10.1007/s10198-016-0842-x
   PubMed Web of Science ®Google Scholar
• Statista. Health, Pharma & Medtech. Health professionals & hospitals. Average cost of inpatient day at U.S. hospitals in 2019, by hospital type. [Internet]. [cited 1 Oct 2022]. Available from: https://www.statista.com/statistics/630443/inpatient-day-hospital-costs-in-us-by-nonprofit-or-profit/.
   Google Scholar
• Cannizzo S, Lorenzoni V, Palla I, et al. Rare diseases under different levels of economic analysis: current activities, challenges and perspectives. RMD Open. 2018;4(Suppl 1):e000794. DOI:10.1136/rmdopen-2018-000794
   PubMedGoogle Scholar
• Gutic M, Milidrag A, Gutic Cikotic A, et al. Rare neurological diseases: an overview of pathophysiology, epidemiology, clinical features and pharmacoeconomic considerations in the treating. Ser J Exp Clin Res. 2021. DOI:10.2478/sjecr-2021-0049
   Google Scholar
• Wellman-Labadie O, Zhou Y. The US orphan drug act: rare disease research stimulator or commercial opportunity? Health Policy. 2010;95:216–228.
   PubMed Web of Science ®Google Scholar
• Iskrov G, Stefanov R. Criteria for drug reimbursement decision-making: an emerging public health challenge in bulgaria. Balkan Med J. 2016;33:27–35.
   PubMed Web of Science ®Google Scholar
• NICE. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2. 2019. [Internet]. [cited 1 Oct 2022]. Available from: https://www.nice.org.uk/guidance/hst12.
   Google Scholar
• Murphy SM, Puwanant A, Griggs RC. Consortium for clinical investigations of neurological channelopathies (CINCH) and inherited neuropathies consortium (INC) consortia of the rare disease clinical research network. Unintended effects of orphan product designation for rare neurological diseases. Ann Neurol. 2012;72:481–490.
   PubMed Web of Science ®Google Scholar